Brachytherapy – Optional Treatment for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration by B. Šarić et al.
Coll. Antropol. 25 Suppl. (2001) 89–96
UDC 617.723-08:617.735-053.9
Professional paper
Brachytherapy – Optional Treatment
for Choroidal Neovascularization
Secondary to Age-Related Macular
Degeneration
B. [ari}, J. [iki}, D. Katu{i} and N. Vukojevi}
Department of Ophthalmology, School of Medicine, University of Zagreb, Zagreb, Croatia
A B S T R A C T
Age-related macular degeneration (ARMD) presents the main cause of irreversible
loss of central vision in older population, due to a progressive neuroretinal damage and
damage of retinal pigment epithelium of foveal area. This observation emphasizes the
insufficiency of all presently used therapeutic procedures. Therefore, investigation has
been conducted at the University Eye Clinic Zagreb for the last three years testing the ef-
fects of brachytherapy with direct episcleral application of ruthenium applicators to the
posterior pole of the globe. Forty-two patients aged 58–79 were followed for a min. of 12
months. During this period their central visual acuities remained stable. Six patients
showed one-line improvement of visual acuity and 8 patients showed no changes.
Twenty-one patient lost 1–2 lines of visual acuity and 7 patients lost more than 2 lines.
According to this we can conclude that patients treated with brachytherapy showed sig-
nificantly better results compared to the control subjects, which is very encouraging.
Introduction
Age-related macular degeneration
(ARMD) presents the leading cause of
blindness. Patients suffering from this
macular disease are handicapped in a
way that they cannot read, write or watch
television. This pathologic process is as-
sociated with the development of choroi-
dal neovascular membrane (CNVM). The-
se »new« blood vessels have been reported
to leak fluid, blood and lipids, which is
followed by fibrovascular scarring bene-
ath and into the retina, causing severe ir-
reversible loss of vision1–4. Although most
patients suffer from a slowly developing
atrophic form of age-related macular de-
generation, 10% of patients have a rap-
idly evolving neovascular form, and among
them 25% develop the same neovascular
process in the fellow eye1,4–6.
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Laser photocoagulation is the only pro-
ven treatment of this disease; however,
less than 20% of patients with well-de-
marcated »classic« CNVMs are eligible
for this treatment7–11. Photocoagulation
results in the destruction of the overlying
retina. Immediately after laser treatment
patients develop dense and poorly toler-
ated central scotoma and experience an
immediate and permanent decline in cen-
tral visual acuity. This kind of treatment
is also associated with an unacceptably
high persistence and recurrence rate of
CNVM7,11–13.
These factors and the progressive aging
of our society place ARMD in the center of
interest of numerous medical investiga-
tions, which have been trying to develop
new modalities of treatment for CNVMs.
These new tretment modalities can be
grouped in four major categories: pho-
todynamic therapy, pharmacologic inhibi-
tion of CNVM formation with antiangio-
genic agents, surgical intervention, and
radiation therapy. All of these experimen-
tal treatment modalities are directed to-
ward destroying CNVMs, and they all
show limitations2,11,14.
Relatively low levels of ionizing radia-
tion have been used to induce regression
of choroidal hemangiomas and other vas-
cular malformations as well as choroidal
tumors without destruction of the overly-
ing retina15,16. Ionizing radiation may
prevent proliferation of endothelial cells
of newly formed subretinal capillaries as
well as induce obliteration of the aber-
rant new vessels17.
The potential of radiation to affect re-
gression of subretinal neovascularization
and its components has led to multiple
clinical trials18–24. Evaluated were radia-
tion doses, dose rates, and radiation de-
livery systems.
Our experience with implant brachy-
therapy led us to expect that the use of
ophthalmic plaques might decrease com-
plications caused by the radiation dose
delivered to most normal ocular (neo-
vascular glaucoma, ishemic optic neurop-
athy, choroidal teleangiectasia, venous
occlusion, edematous retinopathy with
exudation and choroidal hematoma), pe-
riocular, and intracranial structures,
compared to the external beam radiothe-
rapy25–28. Presented are methods of appli-
cation and our preliminary clinical find-
ings after ophthalmic plaque radiothe-
rapy for CNVM secondary to age-related
macular degeneration.
Patients and Methods
A prospective clinical trial was per-
formed. Forty-two patients with subre-
tinal CNVM were referred to brachy-
therapy because they were untreatable
according to Macular Photocoagulation
Study criteria. Control group consisted of
27 patients who refused laser or irradia-
tion therapy. To be included in the study
group, patients had to fulfill the following
eligibility criteria: (1) angiographic evi-
dence of classic or occult CNVM due to
age-related macular degeneration; (2) in-
volvement of the foveal avascular zone;
(3) best-corrected visual acuity of 0.05 or
better; and (4) CNVM not closer than 1
mm to the edge of the optic disc.
All the patients had developed classic
or occult CNVM and had noted recent vi-
sual loss or metamorphosis before they
were included in this study. The study
group consisted of 42 patients (20 men
and 22 women). The mean age was 70
years (range, 58 to 79 years). Min. fol-
low-up period was 12 months after which
patients showed stabilized central visual
acuity. According to fluorescein angio-
graphy performed before surgery, 24 pa-
tients were classified as occult and 18 as
classic CNVM. The control group was
very similar to the study group according
to age, sex and CNVM type distribution
(Table 1).
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Each patient underwent a complete
initial ophthalmic examination. After re-
fraction (best-corrected visual acuity) and
applanation tonometry, direct/indirect,
contact/noncontact, slit-lamp ophthalmo-
scopic techniques were used as required.
Fundus photography as well as fluores-
cein angiography were performed at the
initial visit and again immediately before
surgery, because of the rapid growth of
CNVM. Smallness of these lesions requi-
red standardized A-scan and interpolated
A/B scan ultrasonography to measure re-
tinal depth (chorioretinal thickness at the
macula). Dosimetric calculations showed
very little difference between average ret-
inal depth and default depth of 2 mm.
Ruthenium 106 ophthalmic applicator
model CCB (Bebig/Berlin-Germany) was
used. Dosimetric calculations were per-
formed according to the Collaborative Oc-
ular Melanoma Study protocol29–32 in col-
laboration with medical physicists.
To facilitate surgical procedure plaque
implantation was performed under gen-
eral anesthesia. After conjunctival peri-
tomy and opening of Tenon’s fascia in
temporal quadrants, sterile radioactive
applicator was gently slid underneath the
lateral rectus muscle toward the poste-
rior sclera correspondent to macula. The
posterior edge of the applicator was gen-
tly pushed toward the optic nerve. Epi-
scleral sutures were placed through the
suture eyelets to secure the plaque. Indi-
rect ophthalmoscopy and transscleral il-
lumination were used to confirm the posi-
tion of the applicator. Subconjunctival
anesthetic, antibiotic, and corticosteroid
was given after the closure of the conjunc-
tiva. Surgical removal of the applicator
was performed under local anesthesia.
Patients were treated with a maxi-
mum dose of 24–26 Gy (mean, 25 Gy) to
the overlying retina, in a period of 22–48
hours (mean, 36 hours). Radiation side ef-
fects were not registered. The only post-
operative complication in our study was
transient diplopia which developed in 6
patients, but diminished within a month.
Ophthalmic examinations consisting
of visual acuity check, ophthalmoscopy,
fundus photography and fluorescein an-
giography were scheduled to be perfor-
med at a minimum of 3-month intervals
for at least one year.
Results
Ophthalmic plaque irradiation was
found to be capable of delivering the effi-
cacious dose of irradiation to the area of
choroidal neovascular membrane without
exceeding the threshold dose considered
to cause radiation retinopathy or other
radiation complications in normal human
eyes described in other researches28,33–35.
Since June 1997, we have treated 42
patients with low-dose radiotherapy for
classic and occult CNVM. Presented are
results of 24 patients with occult and 18
patients with classic subretinal choroidal
neovascularization followed for a period
of min. 12 months (Table 2).
After 12 months, ophthalmoscopy and
fluorescein angiography examinations re-
vealed exudative macular lesions marked
as improved, stable or progressive. Im-
proved lesions were defined as having de-
creased or resolved components (hemor-
rhage, exudate, and fluid). Decreased
blood flow was observed in classic neo-
vascular membranes, while lower fluo-
rescence was observed in occult neovas-
cular membranes. Stable lesions were
found to be relatively unchanged or only
slightly enlarged with minimal regres-
sion of components. Progressive lesions
were found increased in size or with more
components. Overall, 23 (54.8%) lesions
were noted stable or improved after the
follow-up period of 12 months following
brachytherapy. In the same period, occult
CNVM group showed better results, with
16 out of 24 (66.6%) lesions being stable
or improved, than classic CNVM group,
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TABLE 2
RESULTS OF RUTHENIUM 106 PLAQUE RADIOTHERAPY FOR CNVM


































































































































































































































































































with 7 out of 18 (38.8%) lesions being sta-
ble or improved (Figure 1). In control
group no improvement was registered
and only 8 out of 27 (29.6%) lesions were
found to be stable (Figure 2). By compar-
ing radiotherapy and control group sta-
tistically significant difference was found
( = 4.20 / p < 0.05). During the follow-up
period, in radiotherapy group 14 eyes
(58.3%) preserved or improved for 1 or
more lines baseline visual acuity, in con-
trast to control group where only 3 eyes
(11.1%) preserved baseline visual acuity
and no eyes showed improvement at all
(Figure 3). The two groups were com-
pared according to initial visual acuities
and visual acuities achieved 12 months
after radiotherapy (Mann-Whitney U test
and T-test for dependent samples). Sta-
tistically significant difference observed
between these two groups (p > 0.001) is
certain evidence of efficacy of radiation
on the improvement and stabilization of
visual acuity.
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Fig. 1. CNVM status 12 months after rutheni-






















































Fig. 3. Visual acuity results in ruthenium 106
plaque radiotherapy group vs. control group af-
ter 12 months follow-up.
Not one patient experienced an imme-
diate irreversible loss of central vision or
complained of scotoma formation associ-
ated with laser treatment. After plaque
radiotherapy we marked resolution of he-
morrhage, exudates, and subretinal fluid.
Till now, no radiation retinopathy, optic
neuropathy, or cataract have been noted.
Discussion
Low dose brachytherapy has been used
to inhibit choroidal neovascularization
growth and reduce scar formation. The
exact mechanism has not been determi-
ned36,37. It has been suggested that radia-
tion may affect the production of cyto-
kines that regulate the production of new
blood vessels38,39, and may directly de-
stroy neovascular endothelial cells. Ra-
diotherapy has also been shown to inhibit
fibroblast proliferation and resultant scar
formation, characteristic for the end-stage
exudative macular degeneration40–42.
We have initiated a prospective clini-
cal study on ophthalmic plaque radio-
therapy for the treatment of choroidal
neovascular membranes. Compared to the
external beam, plaque radiotherapy de-
livers most of the radiation to the tar-
geted macula, whereas all ocular struc-
tures outside the treatment area can be
calculated to receive less irradiation20,44.
For the evaluation of this study, it is
important to note that all of our patients
presented with visual loss, metamorpho-
sis, or both before treatment and most of
them had improved or stabilized vision
after treatment. Irradiated patients show-
ed better visual acuity and retinal status
outcome than the control group. We also
marked better results in occult CNVM
group than in classic CNVM group43.
This study clearly demonstrates that
brachytherapy can be used as an optional
treatment for CNVM in ARMD. It is a
unilateral treatment that allows a large
dose of irradiation to be delivered to the
macula with less irradiation to normal oc-
ular structures, compared to the external
beam radiotherapy. Unlike laser photo-
coagulation, brachytherapy can be used
for subfoveal, both occult and classic,
CNVM. Also, patients do not experience
an immediate irreversible visual loss and
scotoma onset.
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BRAHITERAPIJA – LIJE^ENJE IZBORA U TRETMANU CNVM
KOD ARMD
S A @ E T A K
ARMD (Age-Related Macular Degeneration) predstavlja vode}i uzrok nepovratnog
gubitka centralnog vida u starijoj populaciji, {to nastaje zbog progresivnog o{te}enja
neuroretine i retinalnog pigmentnog epitela foveolarnog podru~ja. Ova ~injenica govori
o neefikasnosti danas poznatih metoda lije~enja. Posljednje tri godine provodimo bra-
hiterapiju direktnom episkleralnom implantacijom rutenijskih aplikatora u projekciji
stra`njeg pola bulbusa. Nakon provedenog tretmana pratili smo 42 pacijenta u dobi od
58–79 godina, kroz period od minimalno 12 mjeseci, nakon kojih dolazi do kona~ne
stabilizacije centralne vidne o{trine. Uo~ili smo pobolj{anje centralne vidne o{trine za
1 ili vi{e redova kod 6 pacijenata, a bez promjene bilo je 8 pacijenata. Pogor{anje vidne
o{trine od 1–2 reda registrirano je kod 21 pacijenta, te za vi{e od 2 reda kod 7 pa-
cijenata. Ovi su rezultati ohrabruju}i jer su zna~ajno bolji od onih u kontrolnoj grupi.
